Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

GIST pipeline

Trial arms side by side.

One row is one arm. A blank cell is n/r. A hazard ratio appears only when the source states it. Weeks stay weeks, and a patient count stays a count.

ClassNone selected

No arms selected. Choose a drug, an arm, or a preset.

Each arm uses its closest stored timepoint inside the window.

Cross-trial values

value

Source: Cited trial source for each arm. The timepoint in the table is the one this chart used.

No selected arm has this endpoint inside the time window.

Show as table
ArmTrialPhasePopulationnComparatorTimepointEstimandAssessorValue

Not shown

Every selected arm is drawn.

26 of 32 arms with a reported figure. Choose arms to narrow the chart.

Imatinib 400 mg. best overall response (complete 5.3% plus partial 46.1%): 51.4%, combined analysis, Sum of label complete response 43 (5.3%) and partial response 377 (46.1%)

Imatinib 400 mg. objective response rate (SWOG): 68.5%, up to 36 months

Imatinib 600 mg. objective response rate (SWOG): 67.6%, up to 36 months

Sunitinib 50 mg. objective response rate (partial responses): 6.8%, interim analysis

Ripretinib 150 mg. objective response rate (BICR): 9%, primary analysis

Ripretinib 150 mg. objective response rate, KIT exon 11 ITT: 23.9%, primary analysis; nominal P = .03

Ripretinib 50 mg. objective response rate, KIT exon 11 ITT: 14.6%, primary analysis

Avapritinib 300 or 400 mg. overall response rate (independent review): 84%, median follow up 10.6 months

Avapritinib 300 or 400 mg. overall response rate (independent review): 89%, median follow up 10.6 months

Avapritinib 300 mg. objective response rate: 17.1%, primary analysis

Avapritinib 160 mg. objective response rate: 7.2%, primary analysis

Bezuclastinib + Sunitinib 600 mg + 37.5 mg. objective response rate (BICR): 46%, data cutoff 09.30.2025

Bezuclastinib + Sunitinib 37.5 mg. objective response rate (BICR): 26%, data cutoff 09.30.2025

Velzatinib (IDRX-42, GSK6042981) 300 mg. objective response rate: 35%, cutoff 12.15.2025

Velzatinib (IDRX-42, GSK6042981) 300 mg. unconfirmed objective response rate: 61%, median follow up 6.4 months

Olverembatinib (HQP1351) 30 to 50 mg. partial response as best response: 23.1%, cutoff 11.13.2025

NB003 not stated in source. objective response rate: 28.5%, data as of March 2025

NB003 not stated in source. objective response rate: 46.7%, data as of March 2025

A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.